Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study)
Open accessAbstract
Patients at risk of coronary heart disease may not achieve recommended low-density lipoprotein (LDL) cholesterol goals on statin monotherapy. This study was designed to investigate the efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe 10 mg in patients at high risk of coronary heart disease. Four hundred sixty-nine patients were randomly assigned to rosuvastatin alone or in combination with ezetimibe for 6 weeks. The primary end point was the percentage of patients achieving the Adult Treatment Panel III (ATP III) LDL cholesterol goal (<100 mg/dl) at week 6. Secondary end points included the percentage of patients achieving other ATP III and 2003 European lipid goals, changes from baseline in lipid, lipoprotein, and inflammatory parameters, and safety and tolerability. Significantly more patients receiving rosuvastatin/ezetimibe than rosuvastatin alone achieved their ATP III LDL cholesterol goal (<100 mg/dl, 94.0% vs 79.1%, p <0.001) and the optional LDL cholesterol goal (<70 mg/dl) for very high-risk patients (79.6% vs 35.0%, p <0.001). The combination of rosuvastatin/ezetimibe reduced LDL cholesterol significantly more than rosuvastatin (-69.8% vs -57.1%, p <0.001). Other components of the lipid/lipoprotein profile were also significantly (p <0.001) improved with rosuvastatin/ezetimibe. Both treatments generally were well tolerated. Rosuvastatin 40 mg was effective at improving the atherogenic lipid profile in this high-risk population. Combination rosuvastatin with ezetimibe 10 mg enabled greater decreases in LDL cholesterol and allowed more patients to achieve LDL cholesterol goals. In conclusion, rosuvastatin plus ezetimibe may improve the management of high-risk patients who cannot achieve goal on maximal statin monotherapy.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Adding ezetimibe to a statin reduces LDL-C by an additional 15-20%.
“Combining ezetimibe with a statin reduces LDL-C by an additional 15 -20%.116”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [116]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944 · see citing works
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011 · see citing works
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467 · see citing works
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902 · see citing works
Pearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., Criqui, M., Fadl, Y. Y., Fortmann, S. P., Hong, Y., Myers, G. L., et al. (2003) · Circulation · doi:10.1161/01.cir.0000052939.59093.45 · Cited by 6,401 · see citing works
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938 · see citing works
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489 · see citing works
Pedersen, T. R. (2004) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2004.08.027 · Cited by 3,098 · see citing works
Smith, S. C., Allen, J. K., Blair, S. N., Bonow, R. O., Brass, L. M., Fonarow, G. C., Grundy, S. M., Hiratzka, L. F., Jones, D. W., Krumholz, H. M., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.174516 · Cited by 2,088 · see citing works
Nissen, S. E., Nicholls, S. J., Sipahi, I., Libby, P., Raichlen, J. S., Ballantyne, C. M., Davignon, J., Erbel, R., Fruchart, J. C., Tardif, J.-C., et al. (2006) · JAMA · doi:10.1001/jama.295.13.jpc60002 · Cited by 2,047 · see citing works
Self-citationHigh Breakdown-Point and High Efficiency Robust Estimates for Regression
Yohai, V. J. (1987) · The Annals of Statistics · doi:10.1214/aos/1176350366 · Cited by 1,676 · see citing works
Jones, P. H., Davidson, M. H., Stein, E. A., Bays, H. E., McKenney, J. M., Miller, E., Cain, V. A., & Blasetto, J. W. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00530-7 · Cited by 1,392 · see citing works
EUROPEAN GUIDELINES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE
Backer, D. D., Амбросиони, Е., Borch‐Johnsen, K., Brotons, C., Cífková, R., Dallongeville, J., Ebrahim, S. B. J., Færgeman, O., Graham, I. D., Mancia, G., et al. (2005) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2005-1-3-57-65 · Cited by 1,268 · see citing works
Ballantyne, C. M., Houri, J., Notarbartolo, A., Melani, L., Lipka, L., Suresh, R., Sun, S. H., LeBeaut, A., Sager, P. T., & Veltri, E. P. (2003) · Circulation · doi:10.1161/01.cir.0000068312.21969.c8 · Cited by 684 · see citing works
Self-citationInhibition of Intestinal Cholesterol Absorption by Ezetimibe in Humans
Sudhop, T., Lütjohann, D., Kodal, A., Igel, M., Tribble, D. L., Shah, S., Perevozskaya, I., & von Bergmann, K. (2002) · Circulation · doi:10.1161/01.cir.0000034044.95911.dc · Cited by 682 · see citing works
Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia
Davidson, M. H., Mcgarry, T. F., Bettis, R. B., Melani, L., Lipka, L., LeBeaut, A., Suresh, R., Sun, S. H., & Veltri, E. P. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02610-4 · Cited by 557 · see citing works
Melani, L. (2003) · European Heart Journal · doi:10.1016/s0195-668x(02)00803-5 · Cited by 271 · see citing works
Davidson, M. H., Maki, K. C., Pearson, T. A., Pasternak, R. C., Deedwania, P. C., McKenney, J. M., Fonarow, G. C., Maron, D. J., Ansell, B. J., Clark, L. T., et al. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.04.019 · Cited by 270 · see citing works
Self-citationBallantyne, C. M., Abate, N. I., Yuan, Ž., King, T. R., & Palmisano, J. J. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.11.023 · Cited by 238 · see citing works
Self-citationEfficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia
Kerzner, B., Corbelli, J., Sharp, S. C., Lipka, L., Melani, L., LeBeaut, A., Suresh, R., Mukhopadhyay, P., & Veltri, E. P. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)03236-8 · Cited by 216 · see citing works
benefit-risk assessment of Rosuvastatin 10 to 40 milligrams
Brewer, H. B. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00779-3 · Cited by 198 · see citing works
Goldberg, A. C., Sapre, A., Liu, J., Capece, R., & Mitchel, Y. (2004) · Mayo Clinic Proceedings · doi:10.4065/79.5.620 · Cited by 191 · see citing works
Rosuvastatin-Induced Arrest in Progression of Renal Disease
Vidt, D. G., Cressman, M. D., Harris, S., Pears, J. S., & Hutchinson, H. G. (2004) · Cardiology · doi:10.1159/000077704 · Cited by 152 · see citing works
Shepherd, J., Hunninghake, D. B., Stein, E. A., Kastelein, J. J. P., Harris, S., Pears, J. S., & Hutchinson, H. G. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.06.049 · Cited by 137 · see citing works
Backer, D. D., Ambrosionie, E., Borch‐Johnsen, K., Brotons, C., Cífková, R., Dallongeville, J., Ebrahim, S. B. J., Færgeman, O., Graham, I. D., Mancia, G., et al. (2003) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/01.hjr.0000120621.99766.ef · Cited by 89 · see citing works
Effect of Short-Term Rosuvastatin Treatment on Estimated Glomerular Filtration Rate
Vidt, D. G., Harris, S., McTaggart, F., et al. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.052 · Cited by 73 · see citing works
Ito, M. K., Delucca, G. M., & Aldridge, M. A. (2001) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424840100600204 · Cited by 28 · see citing works
Backer, D. D., Ambrosioni, E., Borch‐Johnsen, K., et al. (2003) · Bristol Research (University of Bristol) · Cited by 19 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- [20]Barter P, Gotto A, LaRosa J, Grundy S, Bittner V, Fruchart J-C, on behalf of the TNT Steering Committee and Investigators. On-treatment levels of HDL-C and the ratio of LDL-C/HDL-C as predictors of cardiovascular events in the Treating to New Targets (TNT) Study (abstr). J Am Coll Cardiol 2006;47:298A.
- [21]Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW; STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003; 92:152-160.
Cited by
Sorted by citations
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549 · see citing works
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162 · see citing works
Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
Ray, K. K., Bays, H. E., Catapano, A. L., Lalwani, N. D., Bloedon, L. T., Sterling, L. R., Robinson, P. L., & Ballantyne, C. M. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1803917 · Cited by 807 · see citing works
Self-citationESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706 · see citing works
Sullivan, D., Olsson, A. G., Scott, R., Kim, J. B., Xue, A., Gebski, V., Wasserman, S. M., & Stein, E. A. (2012) · JAMA · doi:10.1001/jama.2012.25790 · Cited by 447 · see citing works
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.012 · Cited by 192 · see citing works
Combined therapy in the treatment of dyslipidemia
Reiner, Ž. (2010) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2009.00764.x · Cited by 100 · see citing works
PoLA/CFPiP/PCS guidelines for the management of dyslipidaemias for family physicians 2016
Banach, M., Jankowski, P., Jóźwiak, J., Cybulska, B., Windak, A., Guzik, T., Mamcarz, A., Broncel, M., & Tomasik, T. (2017) · Archives of Medical Science · doi:10.5114/aoms.2017.64712 · Cited by 86 · see citing works
Sharma, M., Ansari, M. T., Abou-Setta, A. M., Soares-Weiser, K., Ooi, T. C., Sears, M., Yazdi, F., Tsertsvadze, A., & Moher, D. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-9-200911030-00144 · Cited by 79 · see citing works
Lavie, C. J., Morshedi‐Meibodi, A., & Milani, R. V. (2008) · Journal of the CardioMetabolic Syndrome · doi:10.1111/j.1559-4572.2008.00002.x · Cited by 61 · see citing works
Niemann-Pick C1-Like 1 (NPC1L1) inhibition and cardiovascular diseases
Pirillo, A., L. Catapano, A., & D. Norata, G. (2016) · Current Medicinal Chemistry · doi:10.2174/0929867323666160229114111 · Cited by 45 · see citing works
Mohammadi, A., Vafaei, S. A., Nabi Moradi, M., Ahmadi, M., Pourjafar, M., & Abbasi Oshaghi, E. (2015) · Avicenna Journal of Medical Biochemistry · doi:10.17795/ajmb-23205 · Cited by 7 · see citing works
- Authors
- Ballantyne, C. M., Weiss, R., Moccetti, T., Vogt, A., Eber, B., Sosef, F., & Duffield, E.
- Affiliations
- Baylor College of Medicine (US)
- Istituto Cardiocentro Ticino (CH)
- Charité – Universitätsmedizin Berlin (DE)
- Barmherzige Schwestern vom heiligen Kreuz (AT)
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Ballantyne, Christie M.
- Venue
- The American Journal of Cardiology
- Publisher
- Elsevier BV
- Published
- 2007-03
- Volume
- 99
- Issue
- 5
- Pages
- 673-680
- ISSN
- 0002-9149 (ISSN-L)
- OpenAlex
- W1985258577
- Cited by
- 196
- References
- 28
- Citations by year
- 2026: 2 · 2025: 11 · 2024: 10 · 2023: 7 · 2022: 6 · 2021: 7 · 2020: 11 · 2019: 10 · 2018: 10 · 2017: 6 · 2016: 11 · 2015: 4 · 2014: 6 · 2013: 4 · 2012: 8
- FWCI
- 22.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The American Journal of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- rosuvastatin, ezetimibe, LDL cholesterol lowering, coronary artery disease, high cardiovascular risk, lipid-lowering therapy, lipoprotein profile, inflammatory markers, drug safety and tolerability
- MeSH terms
- Rosuvastatin Calcium, Ezetimibe, Aged, Azetidines, Cardiovascular Diseases, Dose-Response Relationship, Drug, Drug Therapy, Combination, Female, Fluorobenzenes, Humans, Hypercholesterolemia, Male, Middle Aged, Pyrimidines, Sulfonamides, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
